{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-170509","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2026-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.972741+00:00","generated_at":"2026-05-15T04:55:01.756237+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Definium provides DT120 ODT clinical updates; MDD/GAD readouts in 2H 2026, expansion into PTSD","bullets":["MDD Emerge trial topline data on track for late 2Q 2026; 149 participants randomized 1:1 to DT120 100 µg or placebo.","GAD Voyage trial fully enrolled at 214 participants; topline data expected early 3Q 2026.","GAD Panorama sample size re-estimated to 200; screening closed, topline readout now late 3Q 2026 (previously 2H 2026).","PTSD program expanded with Phase 3 Haven study (~200 pts) initiating in 2027; primary endpoint CAPS-5 at Week 8.","Company presented commercial strategy for DT120 ODT as a potential multi-billion-dollar opportunity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-170509","json":"https://secwatch.observer/filing/0001193125-26-170509.json","markdown":"https://secwatch.observer/filing/0001193125-26-170509.md","text":"https://secwatch.observer/filing/0001193125-26-170509.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526170509/0001193125-26-170509-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526170509/dftx-20260422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:55:01.756237+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}